Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05885607
Other study ID # 853146
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date June 27, 2023
Est. completion date June 2025

Study information

Verified date June 2023
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: - What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i. - Six-minute walk testd - Calf MRI with plantar flexion exercise - Blood sample collection


Description:

Schema Total anticipated enrollment: 40 participants This is an observational study in patients being initiated on an FDA-approved SGLT2i treatment for symptomatic HF (on-label use). This observational study involves supplemental research testing before and after SGLT2i initiation to help define how the treatment affects the body. Study Design This will be a single-center study that will characterize early changes in systemic metabolic and proteomic profiles, skeletal muscle oxidative capacity and six-minute walk distance before and after initiation of SGLT2i treatment. The paired study design will specifically target patients with symptomatic heart failure whose physicians are prescribing FDA-approved SGLT2i treatment. Pre- vs. post-treatment profiling will be performed during the first 4-8 weeks of therapy. Eligibility is not limited to a particular range of LVEF or affected by prior LVEF. Visit Procedures Visit 1: Enrollment/Baseline Visit - Eligibility/Informed Consent - Medical History, Medications Review Visit 2: Pre-SGLT2i Testing - Blood sample collection - Six-minute walk test - Calf MRI with plantar flexion exercise Visit 3: Post-SGLT2i Testing - Blood sample collection - Six-minute walk test - Calf MRI with plantar flexion exercise Study Objectives Primary - Assess the impact of SGLT2i on systemic metabolomic and proteomic profiles Secondary - Assess the impact of SGLT21 on ambulation - Assess the impact of SGLT2i on skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) - Assess the impact of SGLT2i on skeletal muscle perfusion during exercise Study Endpoints - We will measure changes in venous concentrations of metabolic substrates and intermediates, along with circulating proteomic regulators using both targeted and untargeted surveys. - Differences in distance traveled during a standardized 6 minute walk test. - OxPhos as assessed using CrCEST MRI spectroscopy - MRI-based assessment of SkM Perfusion: Differences in conduit artery blood flow and intramuscular perfusion using vPIVOT MRI imaging Risks and Benefits Overview As an observational study, the risks of this research are confined to those associated with the supplemental testing that is being performed: blood sampling, six-minute walk testing and MRI scanning with foot flexion exercise. Blood sampling and six-minute walk testing have minimal risk. After eliminating individuals with absolute contraindications to MRI scanning, such as retained metal fragments or implanted devices that are not MRI compatible, risks related to this MRI study are limited and include feeling uncomfortable in the MRI scanner and developing minor leg discomfort from the one-foot exercise required. Individuals with implanted pacemakers or defibrillators designated as "MRI-conditional" may be included. Subjects who are not eligible for MRI studies may still participate in the blood sampling and six-minute walk test assessments


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date June 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Clinically diagnosed HF documented in the patient's medical record - NYHA Class II-III functional status, according to the most recent clinical evaluation - Availability of an echocardiogram or cardiac MRI within the prior year - Stable HF medical therapy (no change in beta-blocker, ACE/ARB, ARNI or MRA for at least 4 weeks prior to screening) with the exception of diuretics - Planned initiation of on-label SGLT2i therapy Exclusion Criteria: - Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or previous intolerance to an SGLT2 inhibitor - Subject inability/unwillingness to perform a six-minute walk test - Acute coronary syndrome or unstable angina within the past month - Previous cardiac transplantation or implantation of a ventricular assist device - Any condition that will interfere with the completion of the study. This may include comorbid conditions or logistical factors that may impede successful completion of the protocol (e.g. inability to travel for follow-up visits) Absolute Exclusions for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing): - ANY intracranial implants of any type other than dental fillings - ANY non-removable piercings, jewelry, or medicinal patch - ANY personal history of intraocular injury or fragment in or around the orbit that cannot be cleared through radiologic examination - ANY personal history of bullet, shrapnel, or stabbing wounds that cannot be cleared through radiologic evaluation. - ANY non-removable life assist device, pump, or prosthetic Possible Exclusions** for the Leg MRI Assessment (may still participate in blood sampling and six-minute walk testing): - An intra-luminal implant, filter, stent, or valve replacement - A vascular clip or clamp - A surgically placed clip, clamp or band on visceral organs - A cardiac pacemaker or implanted cardiac defibrillator (ICD)##

Study Design


Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the impact of SGLT2i on systemic metabolomic and proteomic profiles We will measure changes in venous concentrations of metabolic substrates and intermediates, along with circulating proteomic regulators using both targeted and untargeted surveys. SGLT2i has been shown to impact glucose, fatty acid, and ketone metabolism. 4-8 weeks
Secondary Assess the impact of SGLT21 on ambulation Differences in distance traveled during a standardized 6-minute walk test. Changes in systemic or skeletal muscle metabolism may improve walking distance. 4-8 weeks
Secondary Assess the impact of SGLT2i on skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) OxPhos as assessed using CrCEST MRI spectroscopy. SkM OxPhos is a major topic of interest for this proposal. We hypothesize that SGLT2i may improve skeletal muscle OxPhos. 4-8 weeks
Secondary Assess the impact of SGLT2i on skeletal muscle perfusion during exercise MRI-based assessment of SkM Perfusion: Differences in conduit artery blood flow and intramuscular perfusion using vPIVOT MRI imaging. Changes in dynamic responses of SkM blood flow may be a contributor to the improvements in exercise tolerance we hypothesize will occur with SGLT2i 4-8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy